

12-4122: Phospho-Chk1 (Ser317) (Clone: G1) rabbit mAb

Clonality :	Monoclonal
Clone Name :	Chk1S317-G1
Application :	FACS,WB
Reactivity :	Human, Mouse
Conjugate :	Unconjugated
Format :	Purified
Alternative Name :	Serine/threonine-protein kinase Chk1, CHK1 checkpoint homolog, Cell cycle checkpoint kinase, Checkpoint kinase-1, CHEK1
Isotype :	Rabbit IgG1k
Immunogen Information :	A synthetic phospho-peptide corresponding to residues surrounding Ser317 of human phospho Chk1

Description

The act of DNA damaged response and cell cycle checkpoints requires the activation of four protein kinases that form the canonical ATR-Chk1 and ATM-Chk2 pathways. ATR activation requires the generation of structures containing single strand DNA (ssDNA) adjacent to double strand DNA (dsDNA). Such ssDNA is coated with replication protein A complex and attracts ATR (1,2). The accumulation of ATR to damage sites results in initial activation of ATR. ATR phosphorylates proteins at the ssDNA which are called checkpoint regulators. The accumulation and phosphorylation of these checkpoint regulators further stimulates the catalytic activity of ATR. ATR-induced Chk1 phosphorylation likely occurs at the sites of DNA damage on chromatin (3-5). The activated ATR phosphorylates Chk1 at Ser317 and Ser345 in its C-terminal regulatory domain. Phospho Chk1 is critical for DNA damage checkpoint activation, replication control, and cell viability (6-8). Functionally, ATR-mediated phosphorylation elevates phospho Chk1 catalytic activity. The N-terminal catalytic domain of Chk1 adopts an open kinase conformation and the deletion of C-terminal domain increases Chk1 catalytic activity.

Product Info

Amount :	20 μ l / 200 μ l
Content :	1X PBS, 0.02% NaN ₃ , 50% Glycerol, 0.1% BSA
Storage condition :	Store at -20°C. Avoid repeated freeze and thaw cycles.

Application Note

1 μ g/mL - 0.001 μ g/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.(0.5mg/ml, more than 200 western blots)




Fig-1: Flow cytometric analysis of K562 cells secondary antibody only negative control (blue) or untreated (red) or treated with IFN α + IL4 + pervanadate (green) using Phospho-Chk1 (S317) antibody Chk1S317-G1 0.1 μ g/mL.




Fig 2 : Western blot analysis of COS7 cell extract untreated or treated with UV+ TPA using Phospho Chk1(S317) antibody ChK1S317-G1 at 0.01 µg/mL.




Fig-3: Peptide blocking flow cytometric analysis of K562 cells secondary antibody only negative control (light blue) or using 0.1 µg/mL of isotype control (orange) or treated with pervanadate and using 0.1 µg/mL of Phospho-Chk1 (S317) antibody Chk1S317-G1 (green) or pervanadate and blocked with phospho peptide (black) or pervanadate and blocked with non-phospho peptide (purple).




Fig-4: Peptide blocking flow cytometric analysis of NIH3T3 cells secondary antibody only negative control (light blue) or using 0.1 µg/mL of isotype control (orange) or treated with IFNa + IL4 + pervanadate and using 0.1 µg/mL of Phospho-Chk1 (S317) antibody Chk1S317-G1 (green) or IFNa + IL4 + Pv and blocked with phospho peptide (black) or IFNa + IL4 + Pv and blocked with non-phospho peptide (purple).